Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Graves Disease II: Pathophysiology

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

Hematopoiesis

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...

Bone Disorders

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Elamipretide in pediatric Barth syndrome: from heart failure to school return.

Orphanet journal of rare diseases·2026

Same author

Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: Results from the European Consortium for Histiocytosis.

HemaSphere·2026

Same author

Are pediatric central nervous system tumors on the rise in France? A population-based 21-year retrospective study.

Cancer epidemiology·2026

Same author

Bilateral Wilms Tumor: Looking for the Best Surgical Strategy.

Annals of surgical oncology·2026

Same author

Splenectomy in β-thalassemia patients: Practices and risks in a nationwide study.

HemaSphere·2026

Same author

Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis.

Blood advances·2026

Search research articles

Related Experiment Videos

Juvenile xanthogranuloma with hematological dysfunction treated with 2CDA-AraC.

Pascale Blouin¹, Marion Yvert, Flavie Arbion

¹Département de Pédiatrie, Unité d'Hémato Oncologie, CHU Tours, Tours, France. p.blouin@chu-tours.fr

Pediatric Blood & Cancer

|July 1, 2010

Summary

Juvenile xanthogranuloma (JXG) in infants can be challenging to treat. Combination therapy with 2-chlorodeoxyadenosine (2CDA) and cytosine arabinoside (AraC) showed promising results in achieving long-term disease control.

Related Experiment Videos

Area of Science:

Pediatric Oncology
Hematology
Dermatology

Background:

Juvenile xanthogranuloma (JXG) is a rare non-Langerhans cell histiocytosis, typically presenting in infants and young children.
JXG can manifest with diverse clinical features, including skin lesions, hepatosplenomegaly, and pancytopenia, posing diagnostic and therapeutic challenges.

Observation:

Two infants diagnosed with JXG presented with skin lesions, hepatosplenomegaly, and pancytopenia.
Initial treatment with vinblastine-steroid-VP16 combination therapy failed to achieve disease control.

Findings:

Subsequent treatment with two courses of 2-chlorodeoxyadenosine (2CDA) and cytosine arabinoside (AraC) led to hematological recovery.
Both patients achieved complete remission with normal blood counts and no signs of JXG at 31 and 24 months post-diagnosis, respectively, after maintenance therapy.

Implications:

The 2CDA and AraC regimen represents a potential effective salvage therapy for infants with severe, refractory JXG.
This case series highlights the importance of exploring alternative treatment strategies for challenging JXG cases.
Further research is warranted to establish the role of 2CDA and AraC in the management of pediatric JXG.